Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2026)

Atea Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 65.26% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $132.9 million (up 56.54% YoY), while the FY2025 annual figure was $188.8 million, up 236.5% from the prior year.
• Cash from Investing Activities was $29.7 million for Q1 2026 at Atea Pharmaceuticals, down from $46.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $124.7 million in Q2 2024 to a low of -$487.0 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$8.3 million across 5 years, with a median of $27.8 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 55736.36% in 2023, then plunged 112.13% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $33.5 million in 2022, then fell by 17.07% to $27.8 million in 2023, then tumbled by 112.13% to -$3.4 million in 2024, then soared by 1482.55% to $46.6 million in 2025, then sank by 36.17% to $29.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $29.7 million (Q1 2026), $46.6 million (Q4 2025), and $41.3 million (Q3 2025), per Business Quant data.